Shots:

• Takeda will lead the development of FIN-524/TAK-524 to treat UC prior to the start of its clinical program & will leverage its expertise in IBD throughout the development process
• Finch plans to provide ongoing technical support through the P-I trial of FIN-524/TAK-524 in the same indication. The companies will continue to advance the program for CD
• In 2017- Takeda & Finch collaborated to develop TAK-524 for IBD under which Finch has received $10M upfront- $4M in milestone- and is eligible to receive an additional ~ $176M as additional milestones along with royalties on WW net sales of the therapy. Finch was primarily responsible for early-stage development activities through P-II study

   Ref: Finch Therapeutics | Image: Finch